Navigation Links
European Cancer Resolution will benefit patients and all those who treat and care for them
Date:4/10/2008

An initiative to combat cancer in the enlarged European Union has been adopted in a plenary session of the European Parliament today (Thursday 10 April). The adoption of the Cancer Resolution has been welcomed by ECCO the European CanCer Organisation which says that patients, and all those who care for them, will benefit if the European Commission and Member States take action on the Resolution's 40 proposals.

ECCO particularly welcomes the proposal that the Commission should revise the Clinical Trials Directive to encourage more academic research on cancer.

Professor Alexander M.M. Eggermont, the President of ECCO, said: We are particularly concerned about the impact of the Clinical Trials Directive, in its present form, on the conduct of clinical trials of cancer treatments. While well intentioned and designed to protect patients interests, we believe that it may well be having the opposite effect. It has set so many regulations in place that the cost of trials has doubled or quadrupled, making it difficult for trials to be run without funding from industry. As a consequence, the number of academically-funded trials is declining, which is bad news for any patients with rare cancers, for patients living in under-resourced countries, and for practitioners who are trying to find better combinations of existing therapies that will be more effective in treating the disease.

This is a serious and undesired effect of the Directive as it threatens academic independence and innovative cancer research and is contrary to the best interests of patients.

Other proposals in the Cancer Resolution include:

  • encouraging the establishment of multi-disciplinary oncology teams in Member States in order to improve treatments for patients and education for all healthcare professionals so that they recognise the psychosocial needs of patients;
  • calling on the Commission to ensure there is adequate funding for co-ordinated research into rare cancers and cancers that are difficult to treat;
  • calling on the Commission to set up an EU Cancer Task Force composed of members of the Commission, the Council of Ministers and the European Parliament to collect and exchange best practice for prevention, screening and treatment and to provide leadership from improved cancer control in Europe;
  • urging Member States to set up statutory cancer registration so that programmes for prevention, screening, treatment and survival can be effectively evaluated;
  • calling on the Commission to encourage and support initiatives to prevent cancer through the promotion of healthy lifestyles, concentrating particularly on children and adolescents, and focusing on major risk factors such as tobacco, alcohol, unhealthy diets and lack of exercise;
  • calling on the Commission and Member States to encourage and promote guidelines on palliative care.

Prof Eggermont said: The European Parliaments vote on the Cancer Resolution is sending an important message to the Commission and Member States that more needs to be done to improve cancer prevention and treatment in Europe.

There are wide disparities between and within individual countries in Europe in the way that cancer is dealt with and consequently in the numbers of people who develop the disease and who survive it. Where you live in Europe can have a significant effect on whether you live or die from cancer, but ECCOs mission is to uphold the right of all European cancer patients to the best possible treatment and care. We hope the Commission and Member States act upon the Cancer Resolution.


'/>"/>

Contact: Emma Mason
wordmason@mac.com
07-711-296-986
ECCO-the European CanCer Organisation
Source:Eurekalert

Related medicine news :

1. New pan-European collaboration launched into the diagnosis and control of coeliac disease
2. European Society for Medical Oncology and European CanCer Organization join forces
3. FORSTEO(R) Receives Approval from the European Commission for the Treatment of Glucocorticoid-Induced Osteoporosis
4. Indevus Pharmaceuticals Licenses European Rights for VANTAS(R) to Orion Corporation
5. IOF recognizes ESCEO European guidance for osteoporosis diagnosis and management
6. More Clinical Data Required to Support European Approval of Desvenlafaxine as a Potential Treatment for Vasomotor Symptoms
7. Gene expression differences between Europeans and Africans affect response to drugs, infections
8. Space sentinels: New tools in space to improve European environment and security policies
9. Boston Scientific Announces First European Implants of New Devices to Treat Heart Failure and Sudden Cardiac Death
10. Specialty European Pharma launches plenaxis in Germany
11. DATATRAK Closes Second Multi-Year Enterprise Agreement with European Clinical Trial Sponsor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2017)... ... May 27, 2017 , ... Most us are familiar with ... new study from the Osteoarthritis Initiative shows that certain people who experience ... this in advance may give doctors the opportunity to treat patients before the problem ...
(Date:5/26/2017)... ... May 26, 2017 , ... Leading CEOs from ... May 30th and 31st at The Four Seasons Hotel Boston. , The ... life sciences, offering exclusive access to key decision makers who influence deal making ...
(Date:5/26/2017)... Clara, Calif. (PRWEB) , ... May 26, 2017 ... ... announces the integration of the CareFusion NOX-T3 portable sleep monitor with its Somnoware ... provides a consistent, browser-based interface for diagnostic device operations. With this platform, initializing ...
(Date:5/26/2017)... ... May 26, 2017 , ... via ... antimicrobial, mesh back 24/7 task chair specifically designed for clinical areas. Genie Copper ... thrilled to partner with Cupron® to provide customers with a game changing chair ...
(Date:5/26/2017)... ... May 26, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House ... focusing on the Peace Agreements being discussed by President Donald Trump and the rest ... to try to speed up peace talks in the continuous battle between Israel and ...
Breaking Medicine News(10 mins):
(Date:5/4/2017)... 2017  A new tight-tolerance microextrusion medical tubing ... materials, is being launched by Natvar, a Tekni-Plex ... in recent years to service a wide variety ... More expensive materials such as glass and fluoropolymers ... to their ability to consistently hold tolerances. This ...
(Date:5/3/2017)... 2017  Kalorama Information notes that transplant diagnostics ... year and this is projected to continue to ... (HSCT) or bone marrow transplants require histocompatibility between ... for this task. This according to a new ... The various PCR-based methodologies, Sanger sequencing and NGS ...
(Date:5/2/2017)... NEW YORK and LONDON ... distributor of market intelligence, MarketResearch.com is pleased to announce ... Consulting AB that allows for the marketing and ... market analyses through the MarketResearch.com website. The ... access to complete product descriptions and tables of contents ...
Breaking Medicine Technology: